A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to the standard treatments. It will also learn about the safety of this new combination antibiotic treatment when compared to the standard treatments. The main questions it aims to answer are:
* How well does Arm D treat mycobacterium abscessus pulmonary disease?
* What side effects does Arm D cause when used to treat mycobacterium abscessus pulmonary disease? Researchers will compare Arm D to the current standard of care treatments to see if Arm D treats mycobacterium abscessus pulmonary disease better and if it will cause less side effects.
Participants will:
* Be screened and recruited to the FORMaT adaptive platform trial (NCT04310930)
* Be given Arm D for 4 weeks or standard of care treatments for 6 weeks.
* Be reviewed by the study doctors weekly for checkups and tests.
* Provide respiratory samples (sample coughed up from the chest), respond to quality-of-life questionnaires, have CT lung scans and blood tests.

开始日期2027-04-01

申办/合作机构

The University of Queensland

[+1]

NCT06801223

/ Recruiting临床1期

A Multicenter, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sulbactam-Durlobactam in Hospitalized Pediatric Patients From Birth to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Acinetobacter Baumannii-calcoaceticus Complex Infection

The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

开始日期2026-10-30

申办/合作机构

Innoviva Specialty Therapeutics, Inc.

[+1]

CTR20191712

/ Completed临床1期

一项评估舒巴坦 ETX2514 在中国健康受试者中单次静脉给药的药代动力学特征、安全性和耐受性的 I 期、开放性临床研究

主要目的在中国健康受试者中，评估以 3 小时持续静脉输注 1.0 g 舒巴坦与 1.0 g ETX2514 单次给药后舒巴坦和 ETX2514 的药代动力学（ PK ）特征。次要目的在中国健康受试者中，评估以 3 小时持续静脉输注 1.0 g 舒巴坦与 1.0 g ETX2514 单次给药后的安全性和耐受性。

开始日期2020-08-05

申办/合作机构

再鼎医药（上海）有限公司

100 项与舒巴坦钠/度洛巴坦钠相关的临床结果

登录后查看更多信息

100 项与舒巴坦钠/度洛巴坦钠相关的转化医学

登录后查看更多信息

100 项与舒巴坦钠/度洛巴坦钠相关的专利（医药）

登录后查看更多信息

项与舒巴坦钠/度洛巴坦钠相关的文献（医药）

2026-02-01·Infectious Diseases

Article

作者: Palavecino, Elizabeth L. ; Kilic, Abdullah

BACKGROUND:

The management of Acinetobacter baumannii infections has become increasingly challenging due to extensive antimicrobial resistance.

OBJECTIVES:

This study evaluated the in vitro activity of cefiderocol and sulbactam-durlobactam and characterised OXA-type enzyme diversity in carbapenem-resistant A. baumannii isolates collected between March 2019 and December 2024.

METHODS:

A total of 159 unique carbapenem-resistant isolates were tested for susceptibility to cefiderocol and sulbactam-durlobactam using two Food and Drug Administration-cleared minimum inhibitory concentration (MIC) determination methods: the ComASP Cefiderocol panel (Liofilchem, Italy) for cefiderocol and Etest strips (bioMérieux, USA) for sulbactam-durlobactam. Carbapenemase genes, including bla_NDM, bla_KPC, bla_IMP, bla_VIM, bla_OXA-23, bla_OXA-24/40, bla_OXA-48, and bla_OXA-58, were detected using real-time PCR.

RESULTS:

Cefiderocol susceptibility was observed in 91.8% of isolates, with MIC₅₀ and MIC₉₀ values of 0.5 mg/L and 2 mg/L. Among bla_OXA-23-positive isolates, MIC₅₀ and MIC₉₀ values were also 0.5 mg/L and 2 mg/L, while bla_OXA-24/40-positive isolates showed MIC₅₀ and MIC₉₀ values of 0.25 mg/L and 1 mg/L, respectively. The sulbactam-durlobactam combination demonstrated potent in vitro activity against 97.5% of carbapenem-resistant Acinetobacter baumannii clinical isolates, with MIC₅₀ and MIC₉₀ values of 2 mg/L and 4 mg/L, respectively. Among the 159 carbapenem-resistant Acinetobacter baumannii isolates, 72.9% (n = 116) carried the bla_OXA-23 gene, 10.7% (n = 17) harboured bla_OXA-24/40, and 16.4% (n = 26) did not possess any of the carbapenemase genes included in the testing panel.

CONCLUSION:

Cefiderocol and sulbactam-durlobactam exhibited strong in vitro activity against carbapenem-resistant A. baumannii isolates from a single University Hospital and may represent valuable treatment options for patients with limited therapeutic alternatives.

2026-01-01·CLINICAL MICROBIOLOGY AND INFECTION

In vitro activity and resistance mechanisms of sulbactam/durlobactam against Acinetobacter baumannii clinical isolates in China (2019–2020)

Article

作者: Yu, Yunsong ; Liu, Haiyang ; Liu, Xiaochen ; Yang, Siyuan ; Xu, Qingye ; Lei, Tailong ; Hua, Xiaoting

OBJECTIVES:

Carbapenem-resistant Acinetobacter baumannii poses a critical threat, with carbapenem-resistance rate exceeding 70% and limited therapeutic options in China. This multicentre study aimed to evaluate in vitro activity and resistance mechanisms of sulbactam/durlobactam (SUL-DUR), a newly approved β-lactam/β-lactamase inhibitor combination in China, against clinical A. baumannii isolates.

METHODS:

A total of 1303 A. baumannii isolates collected nationwide (2019-2020) were investigated. Antimicrobial susceptibility was determined by broth microdilution following clinical and laboratory standards institute guidelines. SUL-DUR-nonsusceptible isolates underwent whole-genome sequencing through Illumina and/or Nanopore, and were assembled using shovill or unicycler. Genomic analyses included sequence typing, resistance gene annotation, single-nucleotide polymorphisms-based phylogenetic reconstruction, and pbp3 mutation mapping. Resistance mechanisms were investigated through quantitative reverse transcription PCR, site-directed mutagenesis, knockout and cloning experiments.

RESULTS:

SUL-DUR demonstrated potent activity, with MIC_50/90 values of 2/4 mg/L and 4/4 mg/L and 95.47% susceptibility. Carbapenem-resistant isolates showed a 32-fold median MIC reduction compared with sulbactam alone, attributed to durlobactam's inhibition of OXA-23 and other β-lactamases. Among 59 nonsusceptible isolates, PBP3 substitutions were the dominant resistance mechanism (48/59, 81.36%), confirmed by MIC reversions in mutagenesis experiments. Residual resistance in some strains implicated efflux pumps and unidentified factors. Six NDM (New Delhi Metallo-β-lactamase) -producing isolates exhibited elevated MICs, among which one strain harboured a novel NDM-87 with higher resistance to SUL-DUR. Genomic analyses highlighted the high-risk ST164 strains carrying chromosomal bla_NDM-1 and the regional dissemination ST2 clones with diverse PBP3 mutations.

CONCLUSIONS:

Despite SUL-DUR's strong efficacy against carbapenem-resistant A baumannii, the emergence of PBP3 mutations and NDM variants highlights the need for vigilant resistance monitoring. This study underscores the importance of integrated surveillance and mechanistic research to optimize SUL-DUR use in China and preserve its therapeutic effectiveness.

2025-01-31·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Durlobactam to boost the clinical utility of standard of care β-lactams against Mycobacterium abscessus lung disease

Article

作者: Sander, Peter ; Negatu, Dereje A. ; Shin, Sung Jae ; Gebresilase, Tewodros T. ; Aragaw, Wassihun Wedajo ; Kaya, Firat ; Paruchuri, Sindhuja ; Dartois, Véronique ; Dick, Thomas

ABSTRACT:

β-Lactams present several desirable pharmacodynamic features leading to the rapid eradication of many bacterial pathogens. Imipenem (IPM) and cefoxitin (FOX) are injectable β-lactams recommended during the intensive treatment phase of pulmonary infections caused by Mycobacterium abscessus (Mab). However, their potency against Mab is many-fold lower than against Gram-positive and Gram-negative pathogens for which they were optimized, putting into question their clinical utility. Here, we show that adding the recently approved durlobactam-sulbactam (DUR-SUL) pair to either IPM or FOX achieves growth inhibition, bactericidal, and cytolytic activity at concentrations that are within those achieved in patients and below the clinical breakpoints established for each agent. Synergies between DUR-SUL and IPM or FOX were confirmed across a large panel of clinical isolates. Through in vitro resistant mutant selection, we also show that adding DUR-SUL abrogates acquired resistance to IPM and FOX. Since the use of β-lactam injectables is firmly grounded in clinical practice during the intensive treatment phase of Mab pulmonary disease, their potentiation by FDA-approved DUR-SUL to bring minimum inhibitory concentration distributions within achievable concentration ranges could offer significant short-term benefits to patients, while novel β-lactam combinations are optimized specifically against Mab pulmonary infections, for which no reliable cure exists.

222

项与舒巴坦钠/度洛巴坦钠相关的新闻（医药）

2026-03-14

·谭谈药市

【太平洋医药|深度】再鼎医药：双引擎驱动长期价值，核心管线加速推进临床

报告摘要核心管线2026年催化剂密集公司重点推进三项Zoci注册性关键临床研究。 2L+ SCLC：评估Zoci对比研究者选择的治疗方案（托泊替康、芦比替定或氨柔比星）在复发性SCLC患者中的疗效和安全性的全球3期研究正在进行中。研究计划入组约480名二线SCLC或塔拉妥单抗经治的三线SCLC患者，大部分入组预计在2026年完成。 1L SCLC：评估Zoci联合疗法（联合阿替利珠单抗±化疗）一线治疗广泛期SCLC的全球1期临床研究正在进行中。预计于2026年下半年读出该研究的数据，并将基于最新数据在2026年推进至注册性研究阶段。公司预计2026年上半年再启动一项1期研究，探索Zoci的新型联合治疗方案。 NECs：2026年1月，正在进行的用于神经内分泌癌（NECs）的全球1b/2期研究的2期部分完成了首例患者给药。预计在2026年上半年公布1b期部分的初步数据，在年内完成2期部分的患者入组，并推进这一研究进入注册性阶段。公司多个管线稳步推进临床开发。ZL-1503（IL-13/IL-31Rα）已完成首例给药，预计2026年下半年披露FIH数据，有望支撑特应性皮炎的2期临床开发。ZL-6201（LRRC15 ADC）已启动全球1期临床研究。ZL-1222（PD1xIL12）预计2026年上半年披露临床前数据。ZL-1311（MUC17 TCE）获全球独家权益，实现TCE领域零的突破，将聚焦胃癌及胃食管结合部癌高表达人群，进一步拓展消化道肿瘤免疫布局。艾加莫德多适应症拓展打开市场空间艾加莫德获中国权威指南最高等级推荐。2025年7月发布的《中国重症肌无力诊断和治疗指南（2025版）》，艾加莫德已被首次正式纳入，并获得最高等级推荐（A级推荐，Ⅰa级证据）。指南推荐艾加莫德不仅可用于快速控制AChR自身抗体阳性的gMG患者症状，也适用于长期的巩固维持，以预防复发。指南建议至少使用3个周期，3个周期后可考虑根据患者个体情况逐渐延长给药间隔，以降低长期复发风险。眼肌型重症肌无力临床取得积极结果。2026年2月，Argenx宣布全球3期研究ADAPT OCULUS达到主要终点（p=0.012），与安慰剂相比，接受艾加莫德治疗的眼肌型重症肌无力（oMG）患者在第四周时，重症肌无力损伤指数患者报告结果（MGII PRO）眼部评分自基线的改善具有统计学上的显著性。在总人群中，艾加莫德治疗组患者的MGII PRO评分自基线的平均变化为改善4.04分，而安慰剂组患者的MGII PRO评分平均变化为改善1.99分。 KarXT有望改变精神分裂症治疗范式 KarXT是全球首个全新机制的抗精神病药物。KarXT主要作用于中枢神经系统M1和M4受体，于2024年9月获得FDA批准上市，2025年12月获得NMPA批准上市，成为抗精神病领域近70年来首个不作用于多巴胺能或5-HT能通路的新机制药物，可显著改善精神分裂症阳性、阴性和认知症状。 KarXT疗效跻身抗精神疾病药物第一梯队。2026年2月，Lancet发表的一项Meta分析通过对比24种抗精神病药物治疗急性精神分裂症的疗效和耐受性发现，新型抗精神病药物毒蕈碱受体激动剂KarXT表现亮眼，总体症状改善标准化均数差达-0.57，与一线抗精神病药物奥氮平持平，疗效跻身前三分之一。 KarXT被纳入两个全国性指南推荐。2025年9月，KarXT作为新型联合制剂被首次写入《中国精神分裂症防治指南（2025版）》。在对精神分裂症症状改善方面，《指南》提到“研究显示该药对阳性症状、阴性症状和认知症状均有效，不具有多巴胺受体阻断活性。”在安全性方面，《指南》提到，KarXT“常见的不良反应是一过性的恶心、消化不良、便秘、呕吐等消化道症状，较少引起催乳素增高、锥体外系不良反应、体重增加、心电图和QT间期改变。” 2026年2月，KarXT被正式纳入《精神分裂症阴性症状管理中国专家共识（2026）》推荐。盈利预测与估值考虑公司创新药新产品快速放量，重点管线多适应症临床开发和申请上市稳步推进，我们预计公司2026/2027/2028年营业收入分别为4.83/5.61/7.80亿美元，同比增速为5%/16%/39%。归母净利润分别为-2.37/-2.18/-0.92亿美元。根据DCF估值模型，参考10年期国债收益率，医药板块平均收益率，假设WACC=9.43%，永续增长率3.00%，测算得出合理市值为249.43亿港元，对应目标股价23.92港元。首次覆盖，给予“买入”评级。风险提示创新药研发不及预期风险；新产品放量不及预期风险；医保支付政策调整带来的风险；地缘政治风险。目录图表目录正文一、中国生物医药产业与全球市场之间的独特桥梁再鼎医药由杜莹博士于2014年创立，是一家以研发为基础、处于商业化阶段的创新型生物制药公司，致力于通过创新产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的巨大医疗需求。通过引进多款潜在重磅产品，推动在中国的商业化，以及自主开发全球创新管线，推进全球临床和上市批准，再鼎医药正成为中国蓬勃发展的生物医药产业与全球市场之间的独特桥梁。 (一)政策支持推动多款重磅产品在中国商业化 8款已商业化产品助力公司稳健增长。根据最新的公司财报（截至2026年3月），再鼎医药在中国已有8款产品成功实现商业化上市。这些产品覆盖了肿瘤、自身免疫及抗感染等多个治疗领域，共同促进公司收入稳健增长且亏损显著缩窄，2018-2025年营业收入年复合增长率为221.3%。 2025年，公司核心产品尼拉帕利（则乐®）在院内销售中继续保持领先地位，实现收入1.89亿美元，艾加莫德（卫伟迦®/卫力迦®）在重症肌无力市场的渗透率和治疗时长持续提升，实现收入0.94亿美元，鼎优乐®（同比+593%）与纽再乐®（同比+41%）销售快速放量。公司全年实现营业收入4.60亿美元（同比+15.3%）。多款潜在重磅产品有望接续上市。公司还有一款备受关注的产品 KarXT（用于治疗精神分裂症）已获得NMPA批准，并计划在2026年上半年正式启动商业化。KarXT为近70年来全球首个新机制精神分裂症疗法，公司计划推进2027年国家医保目录准入，有望成为重要的新增长点。此外，Povetacicept与Elegrobart的关键性临床研究均已启动，分别针对IgA肾病与甲状腺眼病，预计2026年将获得核心数据，有望成为未来收入新增长点。 (二)差异化创新管线加速推进全球临床开发差异化管线重点布局肿瘤和免疫领域。公司近年来通过授权引进快速充实后期临床和商业化产品线，比如KarXT、奥凯乐等。同时大力投入内部研发，专注于ADC、双抗等前沿技术，在肿瘤和自免领域构建具有全球权益的差异化自研产品梯队，比如DLL3 ADC、LRRC15 ADC、IL13/IL31R双抗等。 2026年重点管线临床催化剂密集。Zoci（Zocilurtatug pelitecan）作为首个全球上市潜力肿瘤产品，2026年将推进三项注册性研究，覆盖二线及以上SCLC、一线SCLC及肺外神经内分泌癌，临床数据读出密集，有望奠定全球注册申报基础。此外，ZL-1503（IL-13/IL-31Rα）完成首例给药，预计2026年下半年将披露FIH数据，有望支撑特应性皮炎的2期临床开发。ZL-6201（LRRC15 ADC）已启动全球1期临床研究。ZL-1222（PD1xIL12）预计2026年上半年披露临床前数据。ZL-1311（MUC17 TCE）获全球独家权益，实现TCE领域零的突破，将聚焦胃癌及胃食管结合部癌高表达人群，进一步拓展消化道肿瘤免疫布局。二、全球首创DLL3 ADC适应症拓展潜力大小细胞肺癌领域存在巨大的未满足需求。小细胞肺癌（SCLC）在肺癌中占比约15%，是一种高度侵袭的恶性肿瘤，在接受治疗后5年总生存率仅为5-10%。全球每年新增确诊SCLC患者约37.2万名，其中美国每年新增确诊患者约3.4万，欧盟每年新增确诊患者约7.3万。目前缺乏有效的早期筛查手段，约2/3的SCLC患者确诊时已处于广泛期，仍存在大量未满足的需求。广泛期SCLC的治疗方案有限。广泛期SCLC预后极差，中位生存期仅6-12个月，3年生存率仅为18%，2年生存率仅约5%。一线标准疗法为化疗联合PD-L1抑制剂免疫治疗, 但患者生存期的延长仍然有限（中位总生存期为12~13个月），且多数患者仍会复发，复发后治疗选择有限。靶向DLL3的药物正在改变SCLC治疗格局。2024年5月，全球首个靶向DLL3的塔拉妥单抗获得FDA批准上市，其在SCLC二线治疗中ORR为40%，中位OS达13.6个月(vs化疗8.3个月)。目前多个靶向DLL3的双抗/三抗以及ADC管线快速推进临床，正在迅速改变SCLC的后线治疗格局。现有临床研究发现DLL3 ADC药物在后线治疗中展现了极高的缓解率，尤其是在脑转移患者中显示出独特优势，有望进一步向一线治疗拓展。 Zoci全球关键临床研究快速推进。公司预计2026年将重点推进三项注册性关键临床研究。 2L+ SCLC：评估Zoci对比研究者选择的治疗方案（托泊替康、芦比替定或氨柔比星）在复发性SCLC患者中的疗效和安全性的全球3期研究正在进行中。研究计划入组约480名二线SCLC或塔拉妥单抗经治的三线SCLC患者，大部分入组预计在2026年完成。 1L SCLC：评估Zoci联合疗法（联合阿替利珠单抗±化疗）一线治疗广泛期SCLC的全球1期临床研究正在进行中。预计于2026年下半年读出该研究的数据，并将基于最新数据在2026年推进至注册性研究阶段。公司预计2026年上半年再启动一项1期研究，探索Zoci的新型联合治疗方案。 NECs：2026年1月，正在进行的用于神经内分泌癌（NECs）的全球1b/2期研究的2期部分完成了首例患者给药。预计在2026年上半年公布1b期部分的初步数据，在年内完成2期部分的患者入组，并推进这一研究进入注册性阶段。 Zoci在难治性患者群体中展现出良好的疗效和安全性。根据在2025年AACR-NCI-EORTC国际会议上更新的I期临床研究结果，截至2025年9月15日，研究共纳入115例既往接受过治疗的广泛期SCLC患者，90%的患者既往接受过抗PD-(L)1治疗，44%的患者接受过至少两种前线治疗，32%的患者在基线时存在脑转移，在所有剂量组和所有治疗线数的人群中，未接受过脑部放疗的患者（n=10）ORR达到80%，中位缓解持续时间为6.1个月，32例基线有脑转移的患者中，ORR高达66%。其中1.6 mg/kg剂量组用于二线SCLC治疗（n=19）的ORR为68%，且1.6 mg/kg剂量组的安全性（n=45）良好，3级及以上治疗相关不良事件发生率为13%，未发生2级及以上的间质性肺病，未出现因毒性导致的治疗终止或死亡。三、免疫和神经科学领域产品塑造治疗新格局 (一)艾加莫德–多适应症拓展打开市场空间重症肌无力是一种罕见的自身免疫性疾病。重症肌无力（myasthenia gravis，MG）是一种以乙酰胆碱受体（acetylcholine receptor, AChR）自身抗体介导为主的神经肌肉接头自身免疫性疾病。MG可累及全身骨骼肌，典型临床特征为波动性肌无力和易疲劳，呈“晨轻暮重”，活动后加重、休息后可减轻，眼外肌最易受累，表现为对称或非对称性上睑下垂。最新研究发现，自身抗体可能通过受体阻断、受体内吞和补体激活等机制阻断正常的乙酰胆碱（ACh）与受体的结合过程。重症肌无力疾病负担严重。根据《中国重症肌无力诊断和治疗指南（2025版）》，MG的全球患病率约为12.4/10万人，中国MG的发病率约为0.68/10万人，女性发病率略高于男性。其中，AChR自身抗体阳性成人全身型重症肌无力（gMG）发病率约0.31/10万，每年新增0.4万人。15-20%的MG患者在短期内病情会迅速进展为危及生命的肌无力危象，危象患者死亡率高达11.5%。MG的年龄标准化死亡率为1.86/100万人，其中呼吸系统并发症是造成MG死亡的重要原因之一。重症肌无力传统治疗方案未满足需求大。MG的传统治疗方案包括胆碱酯酶抑制剂（如溴吡斯的明）对症治疗，以及糖皮质激素和免疫抑制剂（如吗替麦考酚酯、他克莫司）等治疗方案。这些方案虽然应用广泛，但存在疗效瓶颈或安全性问题，仍存在较大的未满足临床需求。 FcRn靶向药为重症肌无力治疗提供了更多选择。目前全球范围内，FcRn靶向药艾加莫德、罗泽利昔珠单抗和尼卡利单抗已成功上市，主要用于治疗全身型重症肌无力（gMG），尼卡利单抗已于2025年4月递交中国上市申请，巴托利单抗已于2023年6月递交中国上市申请。艾加莫德可加速清除致病性IgG抗体。艾加莫德（Efgartigimod）是全球首个获批上市的新生儿Fc受体（FcRn）拮抗剂，通过与FcRn结合可导致包括AChR自身抗体在内的致病性IgG抗体被溶酶体加速降解，从而迅速缓解重症肌无力症状。艾加莫德长期疗效确切且稳定。根据ADAPT研究结果，艾加莫德治疗首个周期的MG-ADL和QMG应答率分别为68%和63%；艾加莫德除改善MG-ADL和QMG评分外，还可显著减少MG加重事件发生。根据ADAPT+研究结果，艾加莫德在长期治疗（约3年）中的每个周期都能观察到MG-ADL和QMG评分的改善，使达到有临床意义改善的患者比例进一步提升。各周期最大平均MG-ADL评分改善≥2分的患者比例为89%；QMG评分改善≥3分的患者比例为64.4%。艾加莫德获中国权威指南最高等级推荐。根据2025年7月发布的《中国重症肌无力诊断和治疗指南（2025版）》，艾加莫德基于其确切的长期疗效和安全性，已被首次正式纳入，并获得最高等级推荐（A级推荐，Ⅰa级证据）。指南推荐艾加莫德不仅可用于快速控制AChR自身抗体阳性的gMG患者症状（快速达标治疗），也适用于长期的巩固维持，以预防复发。指南建议至少使用3个周期，3个周期后可考虑根据患者个体情况逐渐延长给药间隔，以降低长期复发风险。眼肌型重症肌无力（oMG）临床取得积极结果。2026年2月，再鼎医药的合作伙伴Argenx宣布，全球3期研究ADAPT OCULUS达到了主要终点（p=0.012），与安慰剂相比，接受艾加莫德治疗的眼肌型重症肌无力（oMG）患者在第四周时，重症肌无力损伤指数患者报告结果（MGII PRO）眼部评分自基线的改善具有统计学上的显著性。在总人群中，艾加莫德治疗组患者的MGII PRO评分自基线的平均变化为改善4.04分，而安慰剂组患者的MGII PRO评分平均变化为改善1.99分。接受艾加莫德治疗的患者的关键眼部症状，包括复视和眼睑下垂，均获得显著改善。此外，2026年1月，基于ADAPT SERON 3期研究结果，FDA受理了艾加莫德用于治疗抗乙酰胆碱受体抗体（AChR-Ab）血清阴性全身型重症肌无力（sn-gMG）成人患者的补充生物制品许可申请（sBLA）的优先审评，处方药用户法案目标行动日期为2026年5月10日。 (二)KarXT–有望改变精神分裂症的治疗范式精神分裂症疾病负担重。精神分裂症多发病于青壮年时期，主要以精神病性症状（与现实接触能力丧失）为特征，其临床表现包括幻觉（错误感知）、妄想（错误信念）、言语和运动行为紊乱，以及阴性症状（情感平淡、情感范围受限）、认知缺陷（推理和解决问题能力受损）以及职业和社会功能受损，且具有高复发性和高致残性的特点。根据文献资料数据，精神分裂症的终生患病率约为0.7%，全球约2400万患者，其中美国约260万，中国约800万。现有药物治疗存在广泛的未满足临床需求。临床现有的第二代抗精神病药物主要作用于多巴胺D2受体和/或5-HT2A受体。现有抗精神病药物普遍对阴性症状和认知症状的疗效有限，且长期服用可能导致锥体外系不良反应或内分泌代谢性不良反应，存在广泛的未满足临床需求。因此，能够改善认知和阴性症状的胆碱能靶点成为了近年来倍受关注的新型抗精神病药物靶点。 M受体参与调节中枢神经和外周内脏活动。乙酰胆碱受体主要分为毒蕈碱型受体（M受体）和烟碱型受体（N受体）两大类。M受体属于G蛋白偶联受体，包括M1-M5五种亚型，主要分布在中枢神经系统、心脏、平滑肌和腺体，可产生副交感神经兴奋效应调节内脏活动。中枢神经系统中M1、M4和M5受体的激活与精神病症状减轻和认知改善有关，而外周M2和M3受体的激活与胃肠道和心血管副作用相关。 KarXT是全球首个全新机制的抗精神病药物。与现有抗精神病药物不同，Karuna和BMS联合开发的KarXT主要作用于中枢神经系统M1和M4受体，于2024年9月获得FDA批准上市，成为抗精神病领域近70年来首个不作用于多巴胺能或5-HT能通路的新机制药物。 KarXT采用“中枢激动+外周拮抗”策略平衡疗效与安全性。KarXT由Xanomeline（中枢M1/M4受体激动剂）和Trospium（M受体拮抗剂）的固定剂量组合构成。Xanomeline作为M1和M4受体的激动剂，能够激活大脑中的毒蕈碱型乙酰胆碱受体，在改善幻觉和妄想等阳性精神症状同时，也可缓解精神分裂症患者的阴性症状，如冷漠、社会驱动力减少，并可提高认知能力。而Trospium作为M受体拮抗剂，能够抑制Xanomeline在外周的心血管和胃肠道副作用，确保药物的安全性和耐受性。 KarXT多项三期临床研究达到主要终点和关键次要终点。KarXT全球EMERGENT系列研究（EMERGENT-1、-2、-3）均成功达到主要终点和关键次要终点，可显著改善精神分裂症阳性、阴性和认知症状。中国III期临床研究ZL-2701-001进一步在本土人群中验证了该药物的疗效与安全性。研究结果显示，在治疗第5周时，KarXT组的阳性与阴性症状量表（PANSS）总分较基线平均降低16.9分，而安慰剂组仅降低7.7分，两组差异达9.2分，具有高度统计学显著性（p=0.0014）。 KarXT在EMERGENT系列研究以及中国桥接研究中表现出症状的持续改善和良好的耐受性。为期52周的EMERGENT-4（N=156）研究结束时，基于PANSS总分评估，69%完成研究的受试者的精神分裂症症状较急性研究基线改善超过了30%。EMERGENT-5（N=566）第52周时，30%的受试者PANSS总分较基线下降≥30%，平均分较基线有-5.5分的下降。总体上KarXT长期治疗的耐受性良好，最常见的TEAE（≥5%）是恶心、呕吐、便秘、口干、腹泻、消化不良、头晕、高血压和嗜睡。大多数TEAE为轻度或中度，不会导致停药。EMERGENT-5研究中，因TEAE导致的停药率为18%。未出现非典型抗精神病药物的常见不良事件（体重增加、静坐不能或迟发性运动障碍、催乳素水平升高等）。 KarXT疗效跻身抗精神疾病药物第一梯队。2026年2月，Lancet发表的一项Meta分析通过对比24种抗精神病药物治疗急性精神分裂症的疗效和耐受性发现，新型抗精神病药物毒蕈碱受体激动剂KarXT表现亮眼，总体症状改善标准化均数差（SMD）达-0.57，与多巴胺受体阻断类抗精神病药物奥氮平持平，疗效跻身前三分之一。在阳性症状改善上，KarXT的SMD为-0.59，略高于利培酮和奥氮平。 KarXT在全球被纳入首个国家级指南。2025年9月，KarXT作为新型联合制剂被首次写入《中国精神分裂症防治指南（2025版）》。在对精神分裂症症状改善方面，《指南》提到“研究显示该药对阳性症状、阴性症状和认知症状均有效，不具有多巴胺受体阻断活性。”在安全性方面，《指南》提到，KarXT“常见的不良反应是一过性的恶心、消化不良、便秘、呕吐等消化道症状，较少引起催乳素增高、锥体外系不良反应、体重增加、心电图和QT间期改变。” 2026年2月，KarXT被正式纳入《精神分裂症阴性症状管理中国专家共识（2026）》推荐。多适应症拓展提升KarXT全球市场空间。2021年11月，再鼎医药以1.87亿美元从Karuna引进KarXT的大中华区权益，2025年12月获得NMPA批准上市。2023年12月，BMS以140亿美元收购Karuna，将KarXT提升至战略核心地位，目前多个适应症全球3期临床正在积极推进中，为后续全球市场开发注入强大资源。四、盈利预测及估值 (一)盈利预测考虑公司创新药新产品快速放量，重点管线多适应症临床开发和申请上市稳步推进，我们预计公司2026/2027/2028年营业收入分别为4.83/5.61/7.80亿美元，同比增速为5%/16%/39%。归母净利润分别为-2.37/-2.18/-0.92亿美元。核心产品收入测算如下： (二)投资建议：给予“买入”评级根据DCF估值模型，参考10年期国债收益率，医药板块平均收益率，假设WACC=9.43%，永续增长率3.00%，测算得出合理市值为249.43亿港元，对应目标股价23.92港元。首次覆盖，给予“买入”评级。五、风险提示 1. 创新药研发不及预期风险创新药研发具有较大不确定性，临床试验过程中影响因素较多，存在临床数据不及预期而研发失败的风险。 2. 新产品放量不及预期风险新产品放量影响因素较多，包括产品竞争格局、销售团队建设等。肿瘤、自免和精神领域可选疗法较多，销售竞争较激烈。 3. 医保支付政策调整带来的风险近年来参加医保谈判的创新药产品逐渐增多，创新药医保价格谈判可能不及预期，医保支付政策可能根据医保基金结余情况进行调整带来的政策风险。 4. 地缘政治风险当前国际关系错综复杂，大国间地缘政治与意识形态竞争加剧，创新药面临一定的地缘政治风险。相关研究报告【太平洋医药|深度】聚焦创新，共赴新程——2026年医药行业投资策略投资评级说明 1、行业评级看好：预计未来6个月内，行业整体回报高于沪深300指数5%以上；中性：预计未来6个月内，行业整体回报介于沪深300指数－5%与5%之间；看淡：预计未来6个月内，行业整体回报低于沪深300指数5%以下。 2、公司评级买入：预计未来6个月内，个股相对沪深300指数涨幅在15%以上；增持：预计未来6个月内，个股相对沪深300指数涨幅介于5%与15%之间；持有：预计未来6个月内，个股相对沪深300指数涨幅介于-5%与5%之间；减持：预计未来6个月内，个股相对沪深300指数涨幅介于-5%与-15%之间；卖出：预计未来6个月内，个股相对沪深300指数涨幅低于-15%以下。公司地址云南省昆明市盘龙区北京路926号同德广场写字楼31楼报告信息注：文中报告节选自太平洋证券研究所已公开发布研究报告，具体报告内容及相关风险提示等详见完整版报告。证券研究报告：《再鼎医药：双引擎驱动长期价值，核心管线加速推进临床》对外发布日期：2026年3月14日证券分析师：谭紫媚资格编号：S1190520090001 邮箱：tanzm@tpyzq.com 证券分析师：张懿资格编号：S1190523100002 邮箱：zhangyi@tpyzq.com 报告发布机构：太平洋证券股份有限公司免责声明太平洋证券股份有限公司（以下简称“我公司”或“太平洋证券”）具备中国证券监督管理委员会核准的证券投资咨询业务资格。本报告仅向与太平洋证券签署服务协议的签约客户发布，为太平洋证券签约客户的专属研究产品，若您并非太平洋证券签约客户，请取消接收、订阅或使用本报告中的任何信息；太平洋证券不会因接收人收到、阅读或关注媒体推送本报告中的内容而视其为太平洋证券的客户。在任何情况下，本报告中的信息或所表述的意见并不构成对任何机构和个人的投资建议，投资者应自主作出投资决策并自行承担投资风险，任何形式的分享证券投资收益或者分担证券投资损失的书面或口头承诺均为无效。本报告信息均来源于公开资料，我公司对这些信息的准确性和完整性不作任何保证。负责准备本报告以及撰写本报告的所有研究分析师或工作人员在此保证，本研究报告中关于任何发行商或证券所发表的观点均如实反映研究人员的个人观点。报告中的内容和意见仅供参考，并不构成对所述证券买卖的出价或询价。我公司及其雇员对使用本报告及其内容所引发的任何直接或间接损失概不负责。我公司或关联机构可能会持有报告中所提到的公司所发行的证券头寸并进行交易，还可能为这些公司提供或争取提供投资银行业务服务。本报告版权归太平洋证券股份有限公司所有，未经书面许可任何机构和个人不得以任何形式翻版、复制、刊登。任何人使用本报告，视为同意以上声明。微信号｜tantanyaoshi

2026-03-06

·北京医学感染与传染研究

抗菌化疗杂志81卷 1-3期

Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期 https://academic.oup.com/jac/issue 50th Anniversary Collection 50周年纪念合集 Review（综述） 1 Artificial intelligence for improving decision-making in bacterial infection management: a narrative review 人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述 Anisia Talianu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470 Reviews（综述） 2 Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America 耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现 Lillian Rose Giarratana and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340 3 Azithromycin resistance in non-typhoidal Salmonella: a review 非伤寒沙门氏菌对阿奇霉素的耐药性：综述 Zhe Zhu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341 4 Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications 抗生素药效动力学：从最低抑菌浓度到高级指标及其应用 Malin Andersson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374 5 Progress in the study of drug resistance mechanism of Bacillus cereus 蜡样芽孢杆菌耐药机制研究进展 Yuhang Zhang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399 6 The curious constraints on clofazimine 氯法齐明的奇特限制 Maple Goh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430 7 Antiplasmid systems: a novel strategy to combat antibiotic resistance 抗质粒系统：对抗抗生素耐药性的新策略 Mohd Asim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472 Systematic Review（系统综述） 8 Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes 欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述 Priya Shastri and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407 9 Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method 用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述 Najla Alabdulkarim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446 Virtual Roundtable（虚拟圆桌会议） 10 Procalcitonin in the management of lower respiratory tract infection and sepsis 降钙素原在下呼吸道感染和败血症治疗中的应用 Ramy H Elshaboury and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298 Original Research（论著） 11 Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients 来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估 Chrisoula Tahtsidou and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427 12 In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis 体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435 13 Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study 评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究 Nicolas Grégoire and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381 14 Real-life use of isavuconazole in Spanish children and adolescents 西班牙儿童和青少年中艾沙康唑的实际使用情况 Natalia Mendoza-Palomar and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394 15 No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis 基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号 Slobodan M Jankovic and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395 16 Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet 成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较 Nirjan Bhattarai and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396 17 Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究 Beibei Liang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398 18 Differences in prescription for impetigo and cellulitis across years in three European countries 三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异 Thomas Bettuzzi and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400 19 β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit 重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度 Karolina Liljedahl Prytz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401 20 Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system 在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较 Jelmer Raaijmakers and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402 21 Identification of antimicrobial resistance genes in Escherichia coli through network diffusion 通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因 Anis Mansouri and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404 22 Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease 依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估 Sanjay Singh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405 23 The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法 Malin Andersson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406 24 Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction 解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系 Maria Montaner and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408 25 Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge 不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战 Ana C Almeida-Santos and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409 26 Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study 在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果 Romain Palich and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410 27 HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda 乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联 Anne Kapaata and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411 28 Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States 美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况 Sarah C J Jorgensen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412 29 Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies 奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究 Saskia E Mudde and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413 30 Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023) 后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023） Mekki F Bensaci and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414 31 Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions 慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联 Gabriel P E Silveira and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416 32 Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis 博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析 Biao Tang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418 33 Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation) 基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释） Yinzheng Zhong and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419 34 Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights 印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察 Shristi Verma and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420 35 Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations 减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示 Yeleen Fromage and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421 36 Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates 基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性 Reham Mostafa and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422 37 Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing 危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药 Sonya Tang Girdwood and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423 38 Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients 达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量 W Töpfer and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424 39 Notable transmitted HIV drug resistance among people who inject drugs in Pakistan 巴基斯坦注射毒品人群中显著传播的HIV耐药性 Stephanie Melnychuk and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425 40 Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium 协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性 Ahmed Ashrin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426 41 Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model 中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究 Panagiota-Christina Georgiou and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431 42 Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp. 非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗 Clayton F Hausberger and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432 43 Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus 阿普拉霉素及其组合对脓肿分枝杆菌的增强活性 Yanqin Huang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433 44 Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene 印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制 Dipika Shaw and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434 45 Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases 鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者 Delphine Girlich and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436 46 Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征 Pengpeng Min and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437 47 Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients 血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性 Thornthun Ueaphongsukkit and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439 48 In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales 头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性 Marion Dutkiewicz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440 49 In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates 舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效 Kirby Patterson-Fahy and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441 50 Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate 利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性 Ruonan Zhao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442 51 Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life? 重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？ Manon Launay and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443 52 National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing 哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析 Ernesto Martínez-Buitrago and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444 53 A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens 基于模型的含固定剂量多替拉韦方案减量策略比较 Laura Dickinson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445 54 Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE) 住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究） Pjotr P Temme and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447 55 Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes 奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究 Jose Valdes Ledesma and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448 56 Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study 采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究 Sacha Kuil and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451 57 High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24 2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高 Josefine Ahlstrand and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452 58 Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable 尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定 Cathia Soulie and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454 59 Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications 延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析 Hannah S Pauw and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455 60 β-Lactam dosing in critically ill children: predictors for target non-attainment 危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素 Stef Schouwenburg and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457 61 Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis 实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况 Barbara Alexander and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461 62 In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes 携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选 Otávio Hallal Ferreira Raro and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462 63 Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input 预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联 María M Montero and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464 64 A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations 全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局 Efi Mantzourani and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466 65 Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus 提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试 Henriëtte M Meliefste and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468 Research Letters（研究快报） 66 Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany 德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731 Henrike Krüger-Haker and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336 67 Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report 厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告 Monica Melchio and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347 68 Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients 来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加 Jose F Camargo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348 69 Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring 达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用 Ambra Barco and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365 70 Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report 血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告 Kohei Hasegawa and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373 71 Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes 使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析 Antoine Hérault and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390 72 Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy 产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播 Gloria D’Achille and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397 73 Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry 来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据 Tommaso Clemente and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415 74 Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker 猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况 Gi Yong Lee and Soo-Jin Yang Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428 75 Importance of reviewing the package insert from gradient strip manufacturers 梯度扩散法药敏纸片生产商说明书审阅的重要性 Mandy Wootton and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429 76 One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene 一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成 Christopher J Harmer and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450 77 Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis 接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿 Cristina Gómez-Ayerbe and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456 78 In vitro activity of gepotidacin against Chlamydia trachomatis 吉皮达星对沙眼衣原体的体外活性 Arabella Touati and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460 Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期 https://academic.oup.com/jac/issue Viewpoints（观点） 1 Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? 长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？ Aleece MacPhail and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471 2 Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies 靶向治疗时代急性白血病抗真菌预防的重新定义 Marcio Nucci and Johan Maertens Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010 Reviews（综述） 3 Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae 替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展 Meilin Wu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504 4 Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations 两性霉素B脂质体与肾脏安全性：证据回顾及临床考量 Johan Maertens and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473 5 Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era 奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略 Keiji Okinaka and Joshua T Schiffer Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489 Systematic Reviews（系统综述） 6 Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis 吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析 Taha Ibrahim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469 7 The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review 产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述 Bruna Abdul Ahad Saad and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476 8 A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae 决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析 Sambit Kumar Dwibedy and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503 9 Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review 促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述 Hester H Stoorvogel and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490 Original Research（论著） 10 Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics 头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究 M B D Nielsen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487 11 Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients 体外膜肺氧合模式对危重患者伏立康唑暴露的影响 Xinrui Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501 12 Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants 基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案 Dustin Huynh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449 13 Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis 铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析 Karolina Anna Mielko-Niziałek and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453 14 In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates 头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性 Carlo Tascini and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467 15 Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands 荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况 Patrick D J Sturm and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475 16 Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant Acinetobacter baumannii 模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用 Xiaonan Zhang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477 17 Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case 加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例 Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478 18 The effect of intrauterine exposure to aminoglycosides on neonatal hearing 宫内暴露于氨基糖苷类抗生素对新生儿听力的影响 Daniel Leshin-Carmel and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483 19 Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies 头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略 Jiaju Zhuo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495 20 Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints 采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果 Xinying Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502 21 Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis 肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况 Pascal Chavanet and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474 22 Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi 用于检测广泛耐药伤寒沙门菌的快速分子诊断技术 Emma L Sweeney and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481 23 Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22 性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析 Deepshikha Batheja and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002 24 Real-world evaluation of isavuconazole in children with cancer 伊沙康唑在儿童癌症患者中的现实应用评估 Janine Nijhuis and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485 25 Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study 加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究 Joseph Elikem Efui Acolatse and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003 26 Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan 台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性 Guan-Jhou Chen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488 27 In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates 吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性 Michelle Jayne Cole and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001 28 A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database 基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析 Ye-Lei Zhao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006 29 Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis 基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用 Andres Mazariegos Herrera and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014 30 evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology 运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架 Ryan A Hamilton and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438 31 First characterization of insertions in the HIV-1 integrase-coding region from people with HIV 首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析 Nhat Quang Tu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491 32 Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae 开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法 Caitlin N Daniels and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493 33 Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats 新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究 Hitesh A Kadu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008 34 Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents 欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究 Marika A de Hoop-Sommen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463 35 Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study 门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究 R C Wilson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484 36 Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy 性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响 Maria Vittoria Cossu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024 37 Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock 头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学 Julius J Schmidt and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496 38 Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa 了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制 Yoshinori Yamano and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004 39 Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD 基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响 Yao Liu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500 40 Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia 评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498 Research Letters（研究快讯） 41 False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report 不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告 J Kimmerlin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459 42 Proposal for the nomenclature of tmexCD-toprJ-like gene clusters 关于tmexCD-toprJ样基因簇命名的建议 Chengzhen Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482 43 IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合 Yan Li and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018 Letter to the Editor（致编辑的信） 44 Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes 对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论 Gwénola Marais and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465 45 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply 意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027 ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家） 46 Acknowledgement of Referees 鸣谢审稿专家 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417 CORRECTION（更正） 47 Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial 更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492 Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期 https://academic.oup.com/jac/issue REVIEW（综述） 1 Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations 缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架 Josep M Llibre and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052 2 Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation 成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍 Daniel B Chastain and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055 3 Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future 细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案 Daisuke Fukuda and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054 4 Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions 应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向 Robiul Islam and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064 SYSTEMATIC REVIEW（系统综述） 5 Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis 耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析 Stamatis Karakonstantis and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037 Original Research（论著） 6 The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting 三级门诊常规剂量口服环丙沙星对患者QT间期的影响 Weber Liu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020 7 Bictegravir concentrations in breastmilk of healthy, lactating women without HIV 未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度 L C van der Wekken-Pas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022 8 Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study 从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究 Anastasia Saade and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021 9 Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study 万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究 Tomoyuki Ishigo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012 10 Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用 Jolieke A T van Osch and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033 11 Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies 体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响 Jie Gao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032 12 Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease 用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究 Seef Abdalla and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019 13 Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24 2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总 Robyn Thorington and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007 14 Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool 使用新型决策支持工具改进围手术期预防性抗生素处方 Mark Mcintyre and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015 15 Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study 针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究 Ángel Rodríguez-Villodres and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034 16 Impact of eravacycline on fibrinogen 依拉环素对纤维蛋白原的影响 Emily Stevenson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030 17 Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients 原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究 Milo Gatti and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009 18 Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates 从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性 Natsuki Yamanaka and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017 19 In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm 双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究 Si-Ho Kim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031 20 LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效 Xing Xia and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036 21 HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用 Giuseppe Lapadula and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045 22 Pharmacokinetics of colistin in adult critically ill patients in South Africa 南非成人危重症患者中多黏菌素的药代动力学研究 Veshni Pillay-Fuentes Lorente and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011 23 Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24) 2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测 Su Chen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016 24 Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study 短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究 Beatriz Borjabad and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040 25 Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials 美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析 Priscilla Y Hsue and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005 26 Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection 采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究 Thomas Lin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039 27 Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries 撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式 Abubaker Ibrahim Elbur and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497 28 Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study 老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究 Arnaud De Clercq and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048 29 Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations 基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案 Wenyan Li and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499 30 Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study 快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究 Salvatore Rotundo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056 31 Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK 与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析 Laura Ciaccio and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049 32 Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study 英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究 Stephen Hughes and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038 33 Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study 糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究 Win Min Han and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053 34 A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025 基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析 Connor Frey and Parham Elmi Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060 35 Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs 体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据 Huifang Zhang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063 36 Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes 在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果 Laura Pezzati and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035 37 A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa 用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型 Yali Fan and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061 38 Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery 微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果 Quentin Saint-Genis and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071 39 Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers 伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型 Hui Li and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065 40 Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study 利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究 Hester H Stoorvogel and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068 41 Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort 当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据 Katja Wallander and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067 42 Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China 治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究 Litai Qin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073 RESEARCH LETTER（研究快讯） 43 Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy 嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎 Yan Feng and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041 44 The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib 糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击” Bianca Monti and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028 45 Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子 Francesca Romana Massacci and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046 46 HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库 Rémi Rouget and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050 47 An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data 一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告 Pierangelo Chinello and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013 48 Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales 碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法 Hippolyte De Swardt and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066 49 Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence 头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战 Stephen Hughes and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051 LETTERS TO THE EDITOR（致编辑的信） 50 Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Chris Kenyon Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025 51 Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply 来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权 Jose F Camargo and Anthony D Anderson Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043 52 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply 意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026 53 Comment on: Artificial intelligence for improving decision-making in bacterial infection management 述评：人工智能在细菌感染管理决策中的优化作用 Daniele Roberto Giacobbe Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078 CORRECTION（更正） 54 Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study 更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494 55 Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing 更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057

2026-03-03

·闲话医健

再鼎医药2025营收同比增长15%

根据再鼎医药公布的2025年第四季度及全年财务业绩，公司在2025年实现了稳健增长，总收入达到4.602亿美元，同比增长15%，同时亏损显著收窄。以下是根据财报及相关资料整理的核心业绩、重要里程碑及未来展望。 2025年核心业绩：增长与优化 2025年，再鼎医药在财务表现上呈现出“收入稳健增长、亏损显著收窄”的良性态势，并持续优化资源配置。 1. 主要财务数据 2025年总收入 4.602亿美元，同比增长15% ，产品收入净额 4.572亿美元同比增长15% ，净亏损 1.755亿美元，同比收窄31.7% 。研发开支 2.209亿美元下降6% 6。 2. 各主要产品表现 · 鼎优乐（肿瘤电场治疗）：成为核心增长引擎。2025年全年收入2，290万美元，受强劲需求推动，同比激增593%，但部分受供应限制影响。 · 纽再乐（抗生素）：表现稳健。全年收入6，080万美元，同比增长41%，主要得益于市场覆盖率和渗透率的提升。 · 则乐（PARP抑制剂）：巩固市场地位。全年收入1.890亿美元，在激烈的竞争环境下，仍保持中国内地卵巢癌领域PARP抑制剂的院内销售领军者地位。 · 卫伟迦/卫力迦（艾加莫德）：全年收入9，420万美元。公司正通过扩大医院覆盖和支持更长的治疗周期，进一步巩固其在全身型重症肌无力（gMG）和慢性炎性脱髓鞘性多发性神经根神经病（CIDP）领域的市场地位。 3. 利润与现金流 · 亏损显著收窄：得益于产品收入的增长快于运营开支，以及汇兑损失转为收益，全年净亏损同比收窄31.7%至1.755亿美元。 · 现金流充足：截至2025年底，公司在手现金及等价物、短期投资等合计约7.896亿美元，为公司后续的研发和商业化提供了坚实基础。 2025年重要里程碑：全球管线的突破 2025年是再鼎医药全球创新管线取得显著进展的一年，特别是其潜在“first-in-class”和“best-in-class”的资产加速推进。 · zoci（靶向DLL3 ADC）快速进入关键阶段：作为再鼎医药首个有望在全球上市的肿瘤产品，zoci的研发在2025年高效推进，已快速进入关键性临床阶段。这充分展现了公司中美整合布局的速度和资金效率。 · 早期全球管线的构建：公司推进了多项具有差异化优势的全球创新管线，为长期发展奠定基础，包括ZL-1503（IL-13/IL-31Rα双抗）、ZL-6201（LRRC15 ADC）、ZL-1222（PD-1/IL-12）和ZL-1311（MUC17/CD3 TCE）等。未来展望：2026年及以后的战略重点展望2026年，再鼎医药将围绕关键催化剂节点，推动后期管线的进展并为下一阶段商业化增长做好准备。 · 近期催化剂：预期数据读出与新药上市 · zoci（DLL3 ADC）：计划在2026年底前启动三项注册性研究（覆盖二线及以上小细胞肺癌、一线小细胞肺癌及肺外神经内分泌癌）。同时，预计在2026年内将有三项临床数据读出，包括伴有脑转移患者的颅内缓解数据。 · KarXT：作为重要的新增增长引擎，计划于2026年上半年在中国商业化上市，并为2027年可能纳入国家医保目录（NRDL）做好准备。 · 关键数据公布：Povetacicept（用于IgA肾病）和elegrobart（用于甲状腺眼病）均预计在2026年获得关键性数据读出，有望驱动近期区域性收入增长。 · ZL-1503：预计在2026年下半年公布正在进行的全球1期研究的首次人体（FIH）数据，为特应性皮炎（AD）的2期临床开发奠定基础。 · 长期目标：向全球生物制药领军企业迈进 · 商业化持续增长：公司将通过新产品的上市（如KarXT、TIVDAK、肿瘤电场治疗用于胰腺癌的潜在获批）、现有产品适应症的拓展（如艾加莫德）以及全球项目的推进，实现未来多年的持续增长和财务改善。 · 全球创新兑现：持续投入和推进全球管线，旨在将再鼎医药从一家以区域商业化为主的生物科技公司，逐步发展为可持续发展的全球生物制药领军企业。总体来看，再鼎医药在2025年交出了一份符合预期的成绩单，商业化产品梯队展现出韧性，而研发管线的进展，尤其是zoci的快速推进，为公司的长期价值带来了更多想象空间。2026年，随着多个重要里程碑事件的兑现，将成为验证其转型成效的关键一年。

100 项与舒巴坦钠/度洛巴坦钠相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
医院获得性细菌性肺炎	美国	Entasis Therapeutics, Inc.	2023-05-23
呼吸机相关细菌性肺炎	美国	Entasis Therapeutics, Inc.	2023-05-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
鲍氏不动杆菌感染	申请上市	中国	Entasis Therapeutics, Inc.	2023-02-24
鲍氏不动杆菌感染	申请上市	中国	再鼎医药（上海）有限公司	2023-02-24
不动杆菌感染	申请上市	美国	Innoviva, Inc.	2022-11-30
菌血症	临床3期	美国	Entasis Therapeutics, Inc.	2019-09-05
菌血症	临床3期	中国	Entasis Therapeutics, Inc.	2019-09-05
菌血症	临床3期	白俄罗斯	Entasis Therapeutics, Inc.	2019-09-05
菌血症	临床3期	巴西	Entasis Therapeutics, Inc.	2019-09-05
菌血症	临床3期	希腊	Entasis Therapeutics, Inc.	2019-09-05
菌血症	临床3期	匈牙利	Entasis Therapeutics, Inc.	2019-09-05
菌血症	临床3期	印度	Entasis Therapeutics, Inc.	2019-09-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03894046 (ATTACK, Pubmed \| Lancet Infect Dis)	临床3期	不动杆菌感染 carbapenem-resistant ABC	181	Sulbactam-durlobactam	淵遞襯網遞構簾糧遞範(衊簾鑰淵構構範繭繭鬱) = 醖鏇齋顧鏇襯製餘鏇糧衊網鹽繭網選膚糧窪憲 (選糧淵築遞鹽遞獵鏇鏇 ) 更多	积极	2023-09-01
				Colistin	淵遞襯網遞構簾糧遞範(衊簾鑰淵構構範繭繭鬱) = 遞獵憲積遞構積觸淵壓衊網鹽繭網選膚糧窪憲 (選糧淵築遞鹽遞獵鏇鏇 ) 更多
NCT03894046 (FDA) 人工标引	临床3期	医院获得性细菌性肺炎 \| 呼吸机相关细菌性肺炎	177	XACDURO	襯餘鑰憲餘廠窪夢鏇積(願網鏇獵憲廠鬱積窪糧) = 願齋襯醖簾醖廠醖範遞膚繭淵糧蓋膚顧蓋願築 (衊淵遞廠鹹淵顧餘糧糧 ) 更多	积极	2023-05-23
				Colistin	襯餘鑰憲餘廠窪夢鏇積(願網鏇獵憲廠鬱積窪糧) = 繭願膚鏇醖鹽鏇積範膚膚繭淵糧蓋膚顧蓋願築 (衊淵遞廠鹹淵顧餘糧糧 ) 更多
NCT03894046 (ATTACK, CTgov)	临床3期	医院获得性细菌性肺炎 \| 菌血症 \| 碳青霉烯类耐药鲍曼不动杆菌感染 ... 更多	207	Durlobactam+Imipenem/Cilastatin 500 mg/500 mg+Sulbactam (Part A - Group 1)	網範鏇顧襯顧網壓積襯 = 廠獵鏇鹹網鏇鹽鹹選淵鏇夢衊淵製醖鬱繭鹽襯 (繭遞衊遞憲鹹膚遞窪構, 顧構鏇襯艱衊構壓選繭 ~ 艱鹹艱齋繭鬱艱糧壓衊) 更多	-	2023-02-01
				Colistin+Imipenem/Cilastatin 500 mg/500 mg (Part A - Group 2)	網範鏇顧襯顧網壓積襯 = 蓋夢衊築願網壓簾積獵鏇夢衊淵製醖鬱繭鹽襯 (繭遞衊遞憲鹹膚遞窪構, 淵糧築醖廠齋範膚築遞 ~ 壓廠憲蓋壓觸願夢鹽窪) 更多
NCT03894046 (ATTACK, Biospace) 人工标引	临床3期	不动杆菌感染	-	imipenem/cilastatin+Durlobactam/Sulbactam sodium	獵壓淵觸壓夢願顧餘範(鏇築艱選製齋觸醖構襯) = Twice than SUL-DUR 築願襯糧醖窪壓鹹觸淵 (壓鏇築積顧壓獵鑰淵壓 ) 更多	积极	2022-05-17
				imipenem/cilastatin+colistin
ATS2022	N/A	不动杆菌感染	-	SUL-DUR	鬱顧醖艱壓鬱糧簾醖遞(醖襯淵網觸鑰衊醖顧夢) = 餘憲鹽窪觸餘鏇齋憲齋願築衊膚淵壓築齋獵襯 (蓋窪齋襯構醖鬱艱築憲 ) 更多	-	2022-05-15
				Colistin + imipenem/cilastatin	鬱顧醖艱壓鬱糧簾醖遞(醖襯淵網觸鑰衊醖顧夢) = 顧壓鬱鑰觸齋獵夢鏇壓願築衊膚淵壓築齋獵襯 (蓋窪齋襯構醖鬱艱築憲 ) 更多
NCT03445195 (Pubmed \| Antimicrob Agents Chemother) 人工标引	临床2期	急性肾盂肾炎 \| 复杂的尿路感染	80	Imipenem-Cilastatin+Durlobactam	網積鏇衊餘積廠醖蓋廠(簾蓋艱夢積膚鑰憲艱鬱) = 獵膚顧齋積製遞蓋廠構鏇網醖願繭憲夢壓鏇壓 (願蓋淵範獵遞夢構遞簾 )	积极	2020-02-21
				Imipenem-Cilastatin+Placebo	網積鏇衊餘積廠醖蓋廠(簾蓋艱夢積膚鑰憲艱鬱) = 遞醖鏇構繭衊築膚製願鏇網醖願繭憲夢壓鏇壓 (願蓋淵範獵遞夢構遞簾 )
NCT03445195 (CTgov)	临床2期	急性肾盂肾炎 \| 复杂的尿路感染	80	Sulbactam-ETX2514+Imipenem-cilastatin (Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin)	鑰憲範齋衊艱壓築顧鹹 = 鹽選廠鬱淵鹹衊壓遞廠餘鹽願窪衊願淵齋膚夢 (淵蓋鬱鬱襯艱餘衊範襯, 鏇衊齋蓋廠壓襯窪積築 ~ 齋築鹽顧壓廠膚鬱鹽鏇) 更多	-	2019-06-05
				Placebo+Imipenem-cilastatin (Placebo + Imipenem/Cilastatin)	鑰憲範齋衊艱壓築顧鹹 = 壓蓋築觸蓋構積繭夢網餘鹽願窪衊願淵齋膚夢 (淵蓋鬱鬱襯艱餘衊範襯, 憲簾鬱願遞夢網襯齋鹹 ~ 憲觸膚願製鑰淵夢壓願) 更多
NCT03303924 (Pubmed \| Antimicrob Agents Chemother)	临床1期	-	30	ETX2514	廠夢網製壓糧鏇築蓋鏇(積範構蓋衊簾構蓋鹹獵) = 觸醖夢繭遞壓遞繭窪鏇製齋鹽憲壓積醖壓膚選 (憲獵獵製範遞淵願壓願 )	-	2018-11-01
				Sulbactam	廠夢網製壓糧鏇築蓋鏇(積範構蓋衊簾構蓋鹹獵) = 廠夢選壓製積網鹹憲鹹製齋鹽憲壓積醖壓膚選 (憲獵獵製範遞淵願壓願 )